Watgen Medical A/S, a subsidiary of Waturu Holding A/S based in Vejle, develops products aimed at treating atopic dermatitis (eczema) and improving wound care. The company is advancing product development and planning clinical trials to document an anti-inflammatory effect on eczema and improved treatment methods for wound patients. In December 2019 Watgen received an initial capital injection to ensure operations, continue product development, and prepare for an upcoming IPO in the second half of 2020. Waturu expects potential demand of more than 75,000 units by 2025, a figure not included in its current growth plan. Watgen has begun expanding its organization with management and specialized resources focused on atopic dermatitis and chronic wound care. The company’s near-term financial position was strengthened by recent investment agreements totaling DKK 12,195,000.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2019